Vasopressin levels in CSF of Alzheimer patients: Correlations with monoamine metabolites and neuropsychological test performance
- 1 January 1989
- journal article
- research article
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 14 (1-2) , 89-95
- https://doi.org/10.1016/0306-4530(89)90057-7
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer typeActa Neurologica Scandinavica, 2009
- Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia.Journal of Neurology, Neurosurgery & Psychiatry, 1987
- Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjectsPeptides, 1987
- Vasopressin in Alzheimer's disease: A study of postmortem brain concentrationsAnnals of Neurology, 1986
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Biochemical changes in Dementia disorders of Alzheimer type (AD/SDAT)Neurobiology of Aging, 1983
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982
- ARGININE VASOPRESSIN AND CHOLINE ACETYLTRANSFERASE IN BRAINS OF PATIENTS WITH ALZHEIMER TYPE SENILE DEMENTIAThe Lancet, 1980
- Guaranteed Stimulus-Processing in the Evaluation of Memory and LearningCortex, 1980
- Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus MonkeyScience, 1979